Novacyt SA (NCYT)
Industry Medical Devices
Sell
38.00p
Buy
38.90p
0.70p (+1.85%)
Prices updated at 12 Dec 2025, 16:27 GMT
| Prices minimum 15 mins delay
Prices in GBX
Novacyt SA develops and markets solutions in medical cytology. It offers portfolio of cancer and infectious disease diagnostics products and services. It has three reportable segment, Cytology, Diagnostics and Molecular Testing.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | 163.39 |
| 2023 | 32.87 |
| 2022 | 27.31 |
| 2021 | 30.48 |
| 2020 | 76.30 |
| 2019 | 64.00 |
| 2018 | 62.71 |
| 2017 | 63.12 |
| 2016 | 54.89 |
| 2015 | 48.08 |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 1.40 |
| 2024 | 1.89 |
| 2023 | 5.52 |
| 2022 | 1.33 |
| 2021 | 0.97 |
| 2020 | 7.26 |
| 2019 | 0.44 |
| 2018 | 0.95 |
| 2017 | 1.92 |
Price/Forward earnings (YTD)
-
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | -40.85 |
| 2023 | -20.60 |
| 2022 | -15.85 |
| 2021 | -4.65 |
| 2020 | 101.55 |
| 2019 | -20.59 |
| 2018 | -14.35 |
| 2017 | -17.21 |
| 2016 | -25.24 |
| 2015 | -61.38 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 1.48 |
| 2023 | 1.53 |
| 2022 | 1.22 |
| 2021 | 1.30 |
| 2020 | 1.55 |
| 2019 | 2.13 |
| 2018 | 1.61 |
| 2017 | 1.37 |
| 2016 | 1.71 |
| 2015 | 1.63 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
